In order to investigate the efficacy and safety of oral fosinopril, a new phosphorus containing angiotensin converting enzyme inhibitor. a single dose of 10 to 20mg was administered in 23 hypertensive patients with diastolic blood pressure above
95mmHg
and all other anti-hypertensive agents were not administered during 4 weeks of study. Blood pressure and heart rate were measured on the 2nd and 4th week of therapy. The complete blood count with platelet count, blood chemistry by SMA-12 and
serum
electrolytes were performed at the beginning and 4th week of therapy. Any kinds of side effects were actively questioned by the examining physicians.
@ES The following results were obtained :
@EN 1) At the beginning and 4th weeks of therapy, the average systolic and diastolic pressure were 170.0±17.6/101.6±6.1mmHg, 142.7±15.1/87.3±67mmHg respectively. The systolic and diastolic blood pressure were declined statistically
significantly
(p<0.05) throughout the period of treatemtn and diastolic blood pressure of all subjects except 3 patients (86%) was maintained below 90mmHg after 4th week of treatment.
2) There was no significant change in the pulse rate before and after therapy.
3) There were no significant changes in blood chemistry, serum electrolytes, hematologic findings, urinalysis and electrocardiographic findings.
4) Side effects were developed in 5 patients (23%) with dry cough, 3 patients (13%) with headache and 2 patients with facial edema but side effectswere mostly mild in nature without potentially serious episodes.
These results suggested that antihypertensive therapy with once-daily fosinopril was effective and well tolerated in essentral hypertensive patients.
|